The changing landscape of phase II/III metastatic sarcoma clinical trials—analysis of ClinicalTrials.gov

BMC Cancer

Table 4 Combination of two targeted drug Trials

NCT No.	Drug1	Drug2	Targets	Year	Phase	Region	Results
NCT03114527	Ribociclib	Everolimus	CDK, mTOR	2017	Phase II	US	No
NCT02343172	HDM201	LEE011	MDM2, CDK	2015	Phase I\| Phase II	US	No
NCT02008877	ganetespib	Sirolimus	HSP90, CD105	2013	Phase I\|Phase II	US	No
NCT01804374	Sorafenib	Everolimus	Multi-RTK, mTOR	2011	Phase II	Europe	No
NCT01281865	everolimus	imatinib	Multi-RTK, mTOR	2011	Phase I\|Phase II	US	Yes
NCT01206140	Selumetinib	Temsirolimus	MEK, mTOR	2010	Phase II	US	Yes
NCT01016015	Cixutumumab	Temsirolimus	mTOR, IGF-1R	2009	Phase II	US	Yes
NCT00937495	vorinostat	bortezomib	HDAC,26S proteasome	2009	Phase II	US	Yes

Abbreviations: CDK cyclin-dependent kinase, mTOR mammalian target of rapamycin, MDM2 Mouse double minute 2 homolog, HSP90 heat shock protein 90, RTK receptor tyrosine kinase, MEK Mitogen-activated protein kinase kinase, IGF-1R Insulin-like growth factor 1 receptor, HDAC Histone deacetylase

ISSN: 1471-2407